Drug Treatment Policy in the Criminal Justice System: A Scoping Literature Review by Resiak, Danielle & Mpofu, Elias
Drug Treatment Policy in the Criminal Justice System:
A Scoping Literature Review
Danielle Resiak1 & Elias Mpofu1,2 &
James Athanasou1
Received: 17 December 2015 /Accepted: 17 December 2015 /
Published online: 12 January 2016
# Southern Criminal Justice Association 2016
Abstract This scoping review sought to map the emerging evidence on use of harm
minimization drug treatment programs in criminal justice settings. A search of various
data bases including Cochrane Database of Systematic Reviews Medline, ProQuest,
SAGE Premier, Scopus, Taylor & Francis Online, and Web of Science yielded eight
studies that met inclusion criteria. The available evidence suggests increasing adoption
of harm minimization policy oriented programs by countries around the world. Specific
programs adopted include needle and syringe exchange, methadone maintenance,
buprenorphine maintenance and treatment in lieu of incarceration. Each of these
programs has evidence to support their effectiveness in relation to individual harm
reduction, disease reduction, increase treatment retention and reduced criminality. This
article considers implications of the adoption of harm minimization policies by criminal
justice systems.
Keywords Drug treatment policy.Harmminimization .Zero tolerance .Criminal justice
system
Over the past 30 years harm minimization practices have emerged as the single most
influential factor impacting on drug treatment policy (McKeganey, 2011). This
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movement in policy (Levine, 2001 as cited in McKeganey, 2011) is replacing the
repression principles of zero tolerance policies (Stevens, 2011). By national jurisdic-
tion, harm minimisation is supported in Australia, United Kingdom, New Zealand,
Netherlands Switzerland and some areas in the USA (Ritter, 2010). Harm minimization
policies are implemented in Finland to a limited extent (Tourunen, Weckroth, &
Kaskela, 2012) and some Eastern European countries implement partial harm minimi-
zation practices (Clark, 2013). By contrast, Russia adopts a zero tolerance policy
(Golichenko & Sarang, 2013). The purpose of this paper is to map the evidence on
the types of harm minimization programs both within and across national settings, their
extent and the perceived benefit to the criminal justice systems that implement them.
It is also evident in some policy practises that Bgray^ areas exist where a drug is
illegal in some respects but legal in others. For example, in some US jurisdictions
marijuana (cannabis) has been decriminalised and legalised only for medicinal pur-
poses (Garland et al., 2012). Furthermore, criminal justice drug treatment policies are
likely influenced by national or regional prerogatives; and perhaps less so by the
documented evidence of their effectiveness (Clark, 2013). For instance, it has been
reported that those who had indicated prescription drug abuse were less likely to be
criminally charged than participants who indicated heroin abuse (Harris, Jacapraro, &
Rastegar, 2012).
Harm minimization policies are premised on promoting healthy criminal justice
system environments, and public health protections post-incarceration. For instance,
prison custody is effective for early diagnosis and treatment of HIV and AIDS (Rosen,
Golin, Grodensky, May, Bowling, DeVellis, White & Wohn, 2015), especially for
inmates with a history of substance use (Haley, Golin, Farel et al., 2014). HIV and
AIDS treatment adherence with a harm minimization goal is a positive outcome for
inmates with the need for such services. Furthermore, harm minimization programs
such as needle and syringe are associated with a lower risk for contracting HIV,
Hepatitis B and or C (Aspinall et al., 2014). By contrast, zero tolerance laws have
been blamed for the spread of blood born viruses because the incarceration of injecting
drug users exposes them to the prison population where the risk of HIV infection is
highest (Clark, 2013). This appears to be the case in jurisdictions where zero tolerance
drug treatment policy is practiced (Clark, 2013). Zero tolerance policy exposes people
with a history of drug dependency to severe health risks from denied access to essential
medical assistance (Golichenko & Sarang, 2013). If adequate treatment is not offered to
such individuals, adverse outcome consequences can be significant and costly for both
the individual and the community (Gardiner et al., 2012). Moreover, the costs of
incarceration are significantly higher than treatment and without interventions to
prevent reoffending from substance use (Anglin, Nosyk, Jaffe, Urada, & Evans, 2013).
Accordingly, informed decisions based on evidence are needed for best drug
treatment policy and practice (Ritter, 2010). Few studies have addressed drug treatment
policy qualities within the criminal justice system or summarised the available evi-
dence. This scoping review addressed two specific research questions: (a) what are the
drug treatment policy trends in the criminal justice system? (b) what is the relative
effectiveness of types of drug treatment policies (that is, do these treatments support the
health of the user and or community)?
A scoping systematic review seeks to map the evidence for essential qualities to
characterize phenomenon of interest to inform further study (Arksey & O’Malley,
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2005). It is particularly appropriate to study trends in the data for emerging or relatively
under-researched topics or practices.
Method
Search Strategy for Identification of Studies
The Cochrane Database of Systematic Reviews was searched to determine if there were
any previous reviews on drug treatment policy. The search terms used included; justice
system, drug treatment, prisoner, zero tolerance, harm minimization, prison, illicit drug
rehabilitation, substance abuse treatment, criminal justice, drug treatment sentencing or
drug treatment arrest were used interchangeably. The search yielded 21 results although
none of which were on drug treatment policy within the criminal justice system,
justifying the need for this scoping review.
Next, a total of six databases for studies on drug treatment policy in the criminal
justice system were searched: Medline, ProQuest, SAGE Premier, Scopus, Taylor &
Francis Online, and Web of Science. In addition, we also searched specific journals;
American Journal of Criminal Justice, and Drug and Alcohol Review. For each
database searched, the terms: harm minimization, zero tolerance, drug treatment, drug
policy, policy, drug abuse, treatment, drug treatment policy, effectiveness, criminal
justice and programs were used interchangeably. The search limits included peer
reviewed articles written in English and published between 2010 and 2015.
Seven studies that resulted were based on their direct relevance to drug treatment
policy. These were then analysed to consider the type of drug policy trending (see
Fig. 1). With harm minimization policy identified as the prominent drug policy, a
secondary search was conducted to source relevant studies pertaining to drug treatment
programs from this policy approach. Seven studies were subsequently selected for
inclusion in this review.
Data Extraction and Management Studies were selected for inclusion in this review
if they met the following inclusion criteria: (a) an explicit focus on drug treatment
policy relating to any of the stages within the criminal justice system including arrest,
prosecution, trial, sentencing, remand or prison; (b) specific reference to either a Harm
Minimisation or Zero Tolerance policy; (c) reporting on evidence of efficacy; (d)
utilized case studies, cross-sectional, or longitudinal studies.
Results and Discussion
Table 1 presents the key findings from the related studies. The three distinct drug
treatment policy trends affecting those in the criminal justice system were (a) needle
and syringe programs, (b) methadone maintenance/buprenorphine maintenance pro-
grams and (c) treatment in lieu of incarceration programs. Needle and syringe exchange
and methadone maintenance/buprenorphine programs along with treatment in lieu of
incarceration have all been used in a criminal justice setting.
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Outcome measures vary dependent on the drug treatment program studied. In
respect to needle and syringe exchange programs the prevalence of HIV and number
of needles or syringes exchanged are the main outcome measures used in the trending
Fig. 1 Article search process for inclusion in scoping literature review
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literature. Outcome measures used to examine the effectiveness of methadone mainte-
nance have mainly been retention rates for treatment and reduced criminal activity.
Overall harm minimization drug treatments have demonstrated their effectiveness
through the decreased spread of disease, reduced drug use and criminality and reduced
administration of justice costs.
Needle and Syringe Exchange Programs A systematic review of the association
between needle and syringe programs and HIV transmission (Aspinall et al., 2014).
This covered the period 1980–2012 and found an exposure to needle and syringe
exchange programs was associated with a reduction in the transmission of HIV
across all studies indicating its effectiveness among people who inject drugs.
Additional harm reduction strategies could have contributed to the reduction in
HIV observed given the time span of data collection. This may indicate needle
and syringe exchange programs are only a component in the injecting risk and other
HIV risk behaviour reductions.
A cross-sectional study was conducted in China by Luo et al. (2015) to examine the
association between participation in a needle exchange program and HIV infection
among intravenous drug users (n=3494; 55 % with needle and syringe exchange
program at least once in their lifetime). Prevalence of HIV was the primary measure
used. Those who had not participated in a needle and syringe exchange program were
1.67 times more likely to be HIV positive comparatively to those who had participated
in a needle and syringe exchange program. These results indicated substantially lower
risk of HIV infection is associated with participation in a needle and syringe exchange
program among injecting drug users in China.
Similarly, a syringe exchange programs study to reduce HIV infection risk was
conducted in Tallinn Estonia by (Uuskula et al., 2011). The study, which ran over
3 years enrolled a total of 1027 injecting drug user participants (80 % male) and their
mean age was 24–27 years. Implementation of syringe exchange programs was
identified with a decrease in HIV prevalence among new injectors.
A randomized experimental design study was conducted in Baltimore County (Kidorf
et al., 2011). Drug use rates, risky behaviours and illegal activity among newly registered
syringe exchange program participants (18 to 65 years) who inject heroin (n=113) were
observed over a 4 month period and compared to non-participants (n=127). When
baseline differences were controlled for, participants who were enrolled in treatment
reported less days of opioid and cocaine use, injecting drug use, illegal activities and
incarceration compared to participants not enrolled in treatment. The findings of this study
identified the harm reduction benefits of needle and syringe exchange programs.
Methadone Maintenance/Buprenorphine Treatment Programs The transition from
a harm minimization program into incarceration is explored in respect to two eastern
states of the United States of America. Massachusetts and Rhode Island. Rhode Island
routinely force inmates to withdraw from methadone upon incarceration (Fu et al.,
2013). In a study on its deterrent effects on for the use of methadone use by inmates
(n=215), more than half of its participants reported that forced methadone withdrawal
during incarceration was a deterrent for seeking a methadone maintenance treatment in
a community setting.
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Similarly, a randomised clinical trial conducted in the United States (Gordon et al.,
2012) contrasted harm mimimization policy application with 211 pre-release male
inmates with pre-incarceration heroin dependence. The participants were randomly
assigned to one of three treatment conditions; counselling only in prison (n=70),
counselling in prison with transfer to methadone maintenance treatment upon release
(n=70) and counselling plus methadone maintenance in prison continued in a com-
munity based methadone maintenance program upon release (n=71). Participants in
the groups which included methadone maintenance were significantly predicted to
enter and complete treatment.
Buprenorphine maintenance treatment was suggested to be more accessible to
released criminal offenders due to being prescribed buprenorphine as opposed to the
attendance requirements of a methadone maintenance program (Harris et al., 2012).
The rates of criminal charges for primary care clinic based buprenorphine maintenance
therapy were determined (Harris et al., 2012). Demographic and outcome data were
collected for 252 participants who had been given at least one prescription for
buprenorphine. Criminal charges prior to and 2 years after initiation of treatment
obtained from a public database were recorded for each participant. Of the participants
who were opioid-negative for six or more months during the first year of treatment
there was a significant decline in criminal cases. Having recent criminal charges was
significantly associated with criminal charges after treatment initiation according to a
multivariable analysis. Additionally participants who were significantly less likely to
have subsequent criminal charges were those on opioid maintenance treatment prior to
enrolment in office based buprenorphine therapy. The study concluded the initiation of
office based buprenorphine treatment did not have a significant impact on subsequent
criminal charges for participants who had prior criminal charges. This finding may have
resulted due to the less intensive monitoring and psychosocial support offered to
participants comparatively to what is received in methadone maintenance treatment
programs which have reported greater success.
Diversion to Treatment Programs Harm minimization programs where successfully
implemented have significant costs savings to the administration of justice. For in-
stance, The California Substance Abuse and Crime Prevention Act mandates continued
parole with substance abuse treatment in lieu of incarceration for adult offenders
convicted of nonviolent drug offences and parole or probation violators. Anglin et al.
(2013) indicated that the costs of incarceration were greater than the costs of treatment.
The state wide policy effect was estimated as an adjusted saving of $2317 per offender
over a 30 month post-conviction period.
Summary of the Key Findings In respect to the available evidence for needle and
syringe exchange programs, exposure to and participation in needle and syring
programs were associated with a reduction in HIV transmission. This indicates the
programs effectiveness amoung injecting drug users. A decrease in HIV prevalence
among new injectors coincided with the implementation of syringe exchange
programs, and when baseline differences were controlled for, participants who
were enrolled in treatment reported less days of opioid and cocaine use, injecting
drug use, illegal activities and incarceration compared to participants not enrolled
in treatment.
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In the studies which addressed methadone maintenance treatment programs positive
outcomes were also highlighted. Participants in the study conducted by Harris et al.
(2012) were significantly less likely to have subsequent criminal charges if they were
on opioid maintenance treatment prior to enrolment in office based buprenorphine
therapy, indicating a positive effect of methadone maintenance. It was concluded, the
initiation of office based buprenorphine treatment did not have a significant impact on
subsequent criminal charges for participants who had prior criminal charges. This
finding may have resulted due to the less intensive monitoring and psychosocial
support offered to participants comparatively to what is received in methadone main-
tenance treatment programs which have reported greater success.
Treatments in lieu of incarceration were observed to be cost effective. The costs of
incarceration were greater than the costs of treatment. A greater incremental cost saving
was observed through reducing recidivism for ethnic groups and Hispanics who have
markedly higher conviction and incarceration rates, under the Substance Abuse and
Crime Prevention legislation.
Implications for Research and Practice
This scoping review poses implications for drug treatment policy development deci-
sions. If policies are based on evidence then the available literature provides most
support for harm minimisation policy and practices. No evidence was found to support
the effectiveness, cost or otherwise of a zero tolerance policy which merely results in
the offender’s incarceration.
Finding from this study suggest a growing body of evidence for the effectiveness of
harm minimization drug treatment programs. Each of the programs; needle and syringe
exchange, methadone maintenance, buprenorphine maintenance and treatment in lieu
of incarceration had evidence to support their effectiveness in relation to individual
harm reduction, disease reduction, increase treatment retention and reduced criminality.
Given it has been suggested in Clark (2013) some criminal justice drug treatment
policies are likely influenced by national or regional prerogatives; rather than docu-
mented evidence of their effectiveness, this review provides evidence on which some
future policy decisions may be informed.
Ethics of HarmMinimization Policies A difference in opinion has been identified on
drug treatment legislation between the general public and people who inject drugs
(Lancaster et al. (2013)). Nonetheless, there is a general consensus that problems exist
within current drug treatment policy (Garland et al., 2012). Some would argue drug
harm resulting from existing drug laws can only be reduced through legalisation or
decriminalisation of illegal substances (McKeganey, 2011). From a policy perspective,
the costs of incarceration are much greater and less cost effective than harm prevention
strategies (Clark, 2013). Stevens (2011) argues that perhaps the human rights costs to
an individual who uses drugs would also be greater under zero tolerance policy.
Irrespective of the drug treatment policy adopted, people who use illicit drugs are
often underrepresented in the process of drug treatment policy decision making, while
most are directly affected by it (Lancaster, Ritter, & Stafford, 2013). Future drug
10 Am J Crim Just (2016) 41:3–13
treatment policy studies might aim to include people who use drugs in their participant
populations to allow for a more accurate representation of the attitudes surrounding
drug treatment policy.
Dispenser Technology Adoption User oriented or safe drug dispensers are increas-
ingly used in the community, and these would be adaptable for use with prison
populations as part of harm minimization intervention. In Paris syringe dispensing
machines have been installed to allow accessibility to clean syringes at any time to
injecting drug users (Duplessy & Reynaud, 2014). Evidence from their usage suggest
injecting drug users were effectively disposing their used syringes and their ability to do
so was higher than that of people with diabetes or HCV treated patients (Duplessy &
Reynaud, 2014). These technological advances in syringe dispensing machines
allowing data to be collected including; number of needles exchanged or collected
and timeframes for collection suggest prospects for adoption and use in the criminal
justice system within a harm minimization regimen.
Person-Variable Effects Policy effects are mediated by personal variables in their
influence on harm minimization outcomes. Personal variables mediated harm minimi-
zation drug treatment compliance among four drug treatment programs (n=289)
throughout the Greater Los Angeles area (Hampton et al., 2011). This study reported
having hope and motivation could explain treatment adherence among volunteer
participants (79.9 %) more so than those with coercion (21.1 %).
Limitations of the Study
A limitation of this scoping review was the paucity of published literature pertaining to
drug treatment policy in a criminal justice setting. The observed trend in the published
material was towards harm minimisation drug treatment programs. Very little is
published in regard to zero tolerance drug treatment policy and no published literature
was found to support its effectiveness. Additionally, some practices (such as those for
use of drug dispensers) suggest a need for further exploration within criminal justice
populations. Outcome results for harm minimization programs using general popula-
tion participants may not be transferable to those within the criminal justice system.
Nonetheless, positive program outcomes were identified for criminal justice system
populations in limited published studies in relation to some of the harm minimisation
programs.
Conclusions
The evidence on harm minimization drug treatment is accumulating and in need of
scoping to map the main trends which might be important to criminal justice system drug
policy advisement. This study sought to explore drug treatment policy and practices in the
criminal justice system with the purpose of mapping evidence to characterise types of
programs in place, their nature or qualities and comparative worth to purpose. This
mapped evidence suggests the effectiveness of harm minimization policy and programs
which are increasingly being adopted by countries around the world.
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